Ivermectin binds to the extracellular domain of EGFR, inhibiting the activation of EGFR and its downstream signaling cascade ERK/Akt/NF-κB, thereby enhancing the antitumor efficacy of doxorubicin against breast cancer cells [18]. This evidence concerns the gene AKT1 and breast carcinoma.